PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 08:40PM GMT
Release Date Price: €35.13 (-0.82%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good afternoon. I'm Tazeen Ahmad. I'm the Senior SMID Biotech Analyst here at Bank of America Merrill Lynch. It's my pleasure to introduce our next presenting company at our healthcare conference, PTC Therapeutics. Sitting next to me from PTC is Marcio Souza, who's the Chief Operating Officer. We are happy to have you. And maybe you can start off for those people in the audience who may not be as familiar with PTC about a 2-minute introduction of the company.

Marcio Souza
PTC Therapeutics, Inc. - COO

I'll do it in 30 seconds.

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Or a 1-minute introduction about what the current updates -- most recent updates have been, what you focus on and what we could look forward to. And then we'll go from there.

Marcio Souza
PTC Therapeutics, Inc. - COO

Yes. And thanks, Tazeen. Thanks for all of you, and pleasure being here. And I'm sorry, I'm just telling Tazeen I'm

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot